Pazopanib targets several TKIs (among them VEGFR, KIT, PDGFR, and FGFR) to inhibit tumor angiogenesis; it was investigated in a phase II adult glioblastoma trial and did not prolong survival (101). Here, KDR is linked to glioblastoma.